Samsung Biologics to acquire Switzerland's PolyPeptide Group in $1.8 billion all-cash deal
- Posted on July 20, 2026
- By CNBC
- 0 Views
- 1 min read
In brief
Samsung Biologics strengthens its pharmaceutical manufacturing capabilities through a strategic acquisition of Switzerland-based PolyPeptide Group for $1.8 billion USD, equivalent to 2.7 trillion Korean won. This major investment expands Samsung's contract development and manufacturing organization (CDMO) services, enhancing its position in the global biopharmaceutical sector and enabling specialized peptide production expertise.
Summary auto-generated by AI from the original publisher's content. Editorial standards.
Samsung Biologics to acquire Switzerland's PolyPeptide Group in $1.8 billion all-cash deal
Samsung Biologics acquires PolyPeptide Group for 2.7 trillion won ($1.8 billion)
